FN1 and glomerulosclerosis: Notch pathway inhibitors were found to weaken glomerulosclerosis and RIF by decreasing the expression of Jagged1, Notch1, NICD1, HEY1, HES1α-SMA, and fibronectin in uremic rats [50].